Skip to main content
SpringerLink
Log in

Epcoritamab: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Epcoritamab (epcoritamab-bysp; Epkinly™; Tepkinly®) is a subcutaneously administered CD3×CD20 T-cell-engaging bispecific antibody being co-developed by Genmab and AbbVie for the treatment of mature B-cell non-Hodgkin lymphoma subtypes (B-NHLs), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab received its first (conditional) approval on 19 May 2023, in the USA, for the treatment of adult patients with relapsed or refractory (R/R) DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥ 2 lines of systemic therapy. Elsewhere, epcoritamab has received a positive opinion in the EU as a monotherapy for the treatment of adults with R/R DLBCL after ≥ 2 lines of systemic therapy, and is currently under regulatory review in Japan for the treatment of adults with R/R large B-cell lymphoma after ≥ 2 lines of systemic therapy. Clinical development of epcoritamab as monotherapy and in combination with standard of care agents for the treatment of mature B-NHLs is ongoing globally. This article summarizes the milestones in the development of epcoritamab leading to this first approval for R/R DLBCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. AbbVie. EPKINLY™ (epcoritamab-bysp) approved by U.S. FDA as the first and only bispecific antibody to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [media release]. 19 May 2023. https://www.abbvie.com.

  2. Genmab US, Inc. EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use: US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324Orig1s000lbl.pdf. Accessed 21 June 2023.

  3. Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52: 102625.

    Article  PubMed  PubMed Central  Google Scholar 

  4. AbbVie. AbbVie receives positive CHMP opinion for epcoritamab (TEPKINLY®) for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [media release]. 21 July 2023. http://www.abbvie.com

  5. Genmab. Genmab announces submission of Japan New Drug Application (JNDA) for epcoritamab (DuoBody®-CD3xCD20) for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) [media release]. 21 December 2022. http://www.genmab.com.

  6. Genmab. Genmab and AbbVie announce broad oncology collaboration [media release]. 10 June 2020. http://www.genmab.com.

  7. van der Horst HJ, de Jonge AV, Hiemstra IH, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021;11(2):38.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chiu CW, Hiemstra IH, ten Hagen W, et al. Preclinical evaluation of epcoritamab combined with standard of care therapies for the treatment of B-cell lymphomas [abstract no. 1574]. Cancer Res. 2021;81(13):1.

    Google Scholar 

  9. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157–69.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang J. Si H, Wielgos-Bonvallet M, et al. Pharmacodynamic activity of epcoritamab (GEN3013; DuoBody®-CD3xCD20) as monotherapy is maintained in combination with standard of care therapies in patients with diffuse large B-cell lymphoma [abstract no. 3248]. In: 114th Annual Meeting of the American Association for Cancer Research, 2023.

  11. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2023;41(12):2238–47.

    Article  CAS  PubMed  Google Scholar 

  12. Thieblemont C, Karimi Y, Jurczak W, et al. Subcutaneous epcoritamab induces deep, durable complete remissions in relapsed/refractory large B-cell lymphoma: longer follow-up from the pivotal EPCORE NHL-1 trial [oral presentation and abstract no. 94]. In: International Conference on Malignant Lymphoma. 2023.

  13. Genmab. AbbVie and Genmab announce positive topline results from phase 1/2 EPCORE™ NHL-1 trial evaluating epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory follicular lymphoma (FL) [media release]. 28 June 2023. https://www.genmab.com.

  14. Karimi Y, Ghesquieres H, Jurczak W, et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: updated results from the pivotal EPCORE NHL-1 trial [abstract no. 7525]. J Clin Oncol. 2023;41(Suppl 16):7525.

    Article  Google Scholar 

  15. Phillips T, Thieblemont C, Ghesquieres H, et al. Epcoritamab monotherapy provides deep and durable responses including minimal residual disease (MRD) negativity: novel subgroup analyses in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) [abstract no. 4251]. Blood. 2022;140(Suppl 1):9443–5.

    Article  Google Scholar 

  16. Phillips T, Lugtenburg P, Kalsekar A, et al. Improvements in lymphoma symptoms and health-related quality of life in patients with relapsed or refractory large B-cell lymphoma treated with subcutaneous epcoritamab (EPCORE NHL-1) [abstract no. 3580]. Blood. 2022;140(Suppl 1):8022–3.

    Article  Google Scholar 

  17. Falchi L, Clausen MR, Offner F, et al. High complete metabolic response rates with epcoritamab + R-CHOP in previously untreated (1L) high-risk DLBCL, including double-hit/triple-hit: EPCORE NHL-2 update [oral presentation and abstract no. 135]. In: International Conference on Malignant Lymphoma. 2023.

  18. Belada D, Falchi L, Leppä S, et al. Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in high-risk follicular lymphoma, regardless of POD24 status [oral presentation and abstract no. 84]. In: International Conference on Malignant Lymphoma. 2023.

  19. Falchi L, Leslie LA, Belada D, et al. Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R2) for first-line treatment of follicular lymphoma: initial results from phase 1/2 trial [abstract no. 611]. Blood. 2022;140(Suppl 1):1471–3.

    Article  Google Scholar 

  20. Abrisqueta P, Cordoba R, Falchi L, et al. Subcutaneous epcoritamab plus R-Dhax/C in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplant: updated phase 1/2 results [abstract no. 443]. Blood. 2022;140(Suppl 1):1068–9.

    Article  Google Scholar 

  21. Brody J, Wahlin BE, Phillips TJ, et al. Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rates even in pts failing CAR T therapy [abstract no. 7527]. J Clin Oncol. 2022;40(Suppl 16):7527.

    Article  Google Scholar 

  22. Falchi L, Leppä S, Wahlin BE, et al. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): update from phase 1/2 trial [abstract no. 7524]. J Clin Oncol. 2022;40(16 Suppl):7524.

    Article  Google Scholar 

  23. Falchi L, Abrisqueta P, Nijland M, et al. Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: phase 1/2 trial update [abstract no. 609]. Blood. 2022;140(Suppl 1):1464–6.

    Article  Google Scholar 

  24. Eichhorst B, Eradat H, Niemann CU, et al. Epcoritamab monotherapy and combinations in relapsed or refractory chronic lymphocytic leukemia or Richter’s syndrome: new escalation and expansion cohorts in EPCORE CLL-1 [abstract no. OT10]. Hematol Oncol. 2023;41(S2):828–9.

    Article  Google Scholar 

  25. Kater AP, Ye JC, Sandoval-Sus J, et al. Subcutaneous epcoritamab in patients with Richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1) [abstract no. 348]. Blood. 2022;140(Suppl 1):850–1.

    Article  Google Scholar 

  26. Sehn LH, Duell J, Avivi I, et al. Subcutaneous epcoritamab in novel combinations with antineoplastic agents among patients with B-cell non-Hodgkin lymphoma in a phase 1b/2, multicenter, open-label study: assessing safety, tolerability, and preliminary efficacy (EPCORE NHL-5) [abstract no. 5524]. Blood. 2022;140(Suppl 1):12108–9.

    Article  Google Scholar 

  27. Sharman JP, Boccia RV, Doerr T, et al. Phase 2 trial to evaluate safety of subcutaneous epcoritamab monotherapy in the outpatient setting among patients with relapsed or refractory diffuse grade 1–3a large B-cell and follicular lymphoma (EPCORE NHL-6) [abstract no. 4271]. Blood. 2022;140(Suppl 1):9491–2.

    Article  Google Scholar 

  28. Sehn LH, Chamuleau M, Lenz G, et al. Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2 [abstract no. OT28]. Hematol Oncol. 2023;41(S2):849–50.

    Article  Google Scholar 

  29. Falchi L, Morschhauser F, Gribben JG, et al. Phase 3 trial of subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) vs R2 among patients with relapsed or refractory follicular lymphoma (EPCORE FL-1) [abstract no. 4206]. Blood. 2022;140(Suppl 1):9338–9.

    Article  Google Scholar 

  30. Cairo MS, Rocco MA, Bernard J, et al. Phase 1b trial of subcutaneous epcoritamab in pediatric patients with relapsed or refractory (R/R) aggressive mature B-cell neoplasms (EPCORE Peds-1) [abstract]. Blood. 2022;140(Suppl 1):3827–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of Interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. James E. Frampton is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 214 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frampton, J.E. Epcoritamab: First Approval. Drugs 83, 1331–1340 (2023). https://doi.org/10.1007/s40265-023-01930-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-023-01930-4

Search

Navigation